BPI
ARQT icon

BFC Planning, Inc.’s Arcutis Biotherapeutics ARQT Stock Holding History

BFC Planning, Inc.’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5
Closed -$118 – 3430
2026
Q1 		$118 Hold
5
– – ﹤0.01% 2956
2025
Q4 		$145 Buy
+5
New +$128 ﹤0.01% 3050

Other funds holding ARQT

Suvretta Capital Management
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BFC Planning, Inc.'s ARQT Position: Q2 2026 in Review

BFC Planning, Inc. sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 5 shares — an estimated $118 sold.

BFC Planning, Inc. first reported a position in ARQT in Q4 2025 and held it in 2 quarters. The position peaked at $145 in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • BFC Planning, Inc. reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • BFC Planning, Inc. sold 5 Arcutis Biotherapeutics shares in Q2 2026, an estimated $118.
  • BFC Planning, Inc. first reported a position in Arcutis Biotherapeutics in Q4 2025 and held it in 2 quarters.
  • BFC Planning, Inc.'s Arcutis Biotherapeutics position peaked at $145 in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.